A method for treating a retinal disease, comprising a step of administering a pharmaceutically effective amount of a composition which comprises a maple leaf extract to a subject in need thereof, wherein the retinal disease comprises nerve damage or ischemic damage to the retina or macula thereof or degeneration therefrom, and wherein the retinal disease is at least one disease selected from the group consisting of retinal artery occlusion, retinal vein occlusion, retinal periphlebitis, hypertensive retinopathy, diabetic retinopathy, retinopathy of prematurity, sensory neuroretinal inflammation, inflammation of the retinal pigment epithelium, retinitis pigmentosa, angioid streaks, drusen, rhegmatogenous retinal detachment, non-rhegmatogenous retinal detachment, macular degeneration, macular dystrophy, diabetic retinopathy, retinal arteriovenous occlusion, hypertensive retinopathy, retinal aortic aneurysm, retinal ischemic syndrome, radiation retinopathy, retinopathy of prematurity, acute retinal necrosis, retinitis, retinal choroiditis, retinal detachment, retinal tumor, retinal damage due to trauma, and retinal damage due to light.